Gimsilumab: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 225 patientsc19early.org

Gimsilumab for COVID-19

Serious outcome risk
Gimsilumab
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−10%
Mortality (1)−10%
RCTs (1)−10%
Late (1)−10%
00.511.5+
← Gimsilumab
reduces riskIncreased
risk →
c19early.org
October 2026

Gimsilumab COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Criner (DB RCT)−10%1.10 · 0.70–1.80death32/11331/112BREATHE
Late treatment−10%1.10 · 0.72–1.6732/11331/11210% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.67
All studies−10%1.10 · 0.72–1.6732/11331/11210% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6700.511.52+
Rotate screen for more detailsIncrease width for more details
← Gimsilumab
reduces riskGimsilumab
increases risk →
c19early.org
October 2026

Gimsilumab COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Criner (DB RCT)−10%1.10 · 0.70–1.8032/11331/112BREATHE
Late treatment−10%1.10 · 0.72–1.6732/11331/11210% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.67
All studies−10%1.10 · 0.72–1.6732/11331/11210% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6700.511.52+
Rotate screen for more detailsIncrease width for more details
← Gimsilumab
reduces riskGimsilumab
increases risk →
c19early.org
October 2026

Gimsilumab COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Criner (DB RCT)−10%1.10 · 0.70–1.80death32/11331/112BREATHE
Late treatment−10%1.10 · 0.72–1.6732/11331/11210% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.67
All studies−10%1.10 · 0.72–1.6732/11331/11210% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6700.511.52+
Rotate screen for more detailsIncrease width for more details
← Gimsilumab
reduces riskGimsilumab
increases risk →
c19early.org
October 2026

Gimsilumab COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Criner (DB RCT)−10%1.10 · 0.70–1.80death32/11331/112BREATHE
Late treatment−10%1.10 · 0.72–1.6732/11331/11210% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.67
All studies−10%1.10 · 0.72–1.6732/11331/11210% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6700.511.52+
Rotate screen for more detailsIncrease width for more details
← Gimsilumab
reduces riskGimsilumab
increases risk →
c19early.org
October 2026

Gimsilumab COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Criner (DB RCT)−10%1.10 · 0.70–1.8032/11331/112BREATHE
Late treatment−10%1.10 · 0.72–1.6732/11331/11210% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.67
All studies−10%1.10 · 0.72–1.6732/11331/11210% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6700.511.52+
Rotate screen for more detailsIncrease width for more details
← Gimsilumab
reduces riskGimsilumab
increases risk →
c19early.org
October 2026

Gimsilumab COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Criner (DB RCT)−10%1.10 · 0.70–1.80death32/11331/112BREATHE
Late treatment−10%1.10 · 0.72–1.6732/11331/11210% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.67
All studies−10%1.10 · 0.72–1.6732/11331/11210% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6700.511.52+
Rotate screen for more detailsIncrease width for more details
← Gimsilumab
reduces riskGimsilumab
increases risk →